U.S. to Fund Ibogaine Research for Veterans With PTSD in Major Psychedelic Medicine Push

admin · November 13, 2026 · 6 min read

A veteran in silhouette in a bright medical research laboratory as a scientist holds a small glass vial, representing new U.S. ibogaine research for PTSD.

The U.S. government will spend up to $4.9 million to prepare for clinical trials of ibogaine, a powerful psychedelic drug, as a possible treatment for post-traumatic stress disorder in veterans, Health Secretary Robert F. Kennedy Jr. announced on Thursday, November 12.

The funding, awarded through the Advanced Research Projects Agency for Health, known as ARPA-H, will lay the groundwork for future American trials of the drug. It is the latest and most concrete step in the Trump administration’s push to bring psychedelic medicines into mainstream mental health care.

What the funding covers

The ARPA-H awards will support preparations for U.S.-based clinical trials, secure supplies of clinical-grade ibogaine, and build the infrastructure to manufacture the drug in the United States. Research teams led by Mark Cuban’s Cost Plus Drug Company will work on the regulatory, clinical, chemical and engineering foundation for a domestically made ibogaine hydrochloride product intended for potential PTSD treatment.

Kennedy said the drug, if it eventually wins approval, would be priced similarly to generic medicines. The commitment runs over five years, with continued funding tied to research milestones.

Officials were careful to define the limits of the announcement. The awards “do not fund patient treatment or human subject research,” Kennedy said, and they do not authorize clinical trials. The money is meant to get ibogaine ready for trials, not to treat patients now.

A second, larger program for ketamine and psilocybin

The same announcement included a separate $20 million funding opportunity from the National Institute of Mental Health to build a research network studying rapid-acting psychotropic drugs, including ketamine, esketamine and psilocybin, the active compound in magic mushrooms.

The institute will award $10 million in this fiscal year and $10 million in the next, with the recipients to be named in the summer of 2027. The network will study how these fast-acting drugs work and which patients they may help most.

Kennedy also said ARPA-H will fund another ibogaine effort aimed at substance-use disorder, which is expected to be announced by the end of 2026. The administration said in October that it was advancing the first government-funded trials of ibogaine to treat opioid addiction and PTSD.

Background: from executive order to funding

The announcements follow an executive order President Donald Trump signed on April 18, 2026, titled “Accelerating Medical Treatments for Serious Mental Illness,” which directed federal agencies to speed up research into psychedelic therapies. Trump allocated $50 million in April for ibogaine research, including a Texas initiative evaluating the drug specifically in veterans.

The federal pivot has moved quickly in other areas as well. In April, the Food and Drug Administration awarded priority review vouchers to three psychedelic drug candidates, a move designed to compress review timelines from 10 to 12 months to as little as one or two. Earlier this month, the nonprofit Usona Institute submitted a new drug application for its synthetic psilocybin candidate for major depressive disorder.

Ibogaine itself comes from the iboga plant, native to Central Africa, and has been used in traditional ceremonies for generations. In the United States it remains a Schedule I controlled substance, meaning the government classifies it as having no accepted medical use and a high potential for abuse. It also carries a serious known risk: the drug can cause dangerous heart rhythm problems, which have killed people who took it outside medical settings.

Why this matters

PTSD affects millions of American veterans, and existing treatments — talk therapy and a small number of approved drugs — fail to help a large share of patients. Veterans’ groups and researchers have pushed for years to study psychedelics, pointing to early evidence that a single guided session can produce lasting symptom relief where other treatments have not.

The new funding matters for two practical reasons. First, a domestic supply of pharmaceutical-grade ibogaine would remove one of the biggest barriers to American trials, which have so far depended on small, imported supplies. Second, the involvement of Cost Plus Drugs signals an effort to keep any eventual treatment affordable, a contrast with other new psychiatric drugs that have launched at tens of thousands of dollars a year.

At the same time, the announcement arrives as Kennedy faces growing scrutiny in Washington. Senate Democrats opened an investigation into Kennedy this week over whether he misled Congress about a 2019 trip to Samoa, a separate controversy that has nothing to do with the ibogaine funding but underscores the political spotlight on the health secretary.

Latest developments

The ibogaine awards were unveiled at a November 12 press conference, the day after Veterans Day, with Kennedy joined by Department of Veterans Affairs leadership. The $20 million rapid-acting psychotropics program is now open, and award winners are expected in the summer of 2027. A further ARPA-H ibogaine announcement focused on substance-use disorder is expected before the end of the year.

The next major test will be whether the preparatory work leads to investigational new drug applications — the formal FDA filings needed before human trials can begin. Until those applications are approved, ibogaine remains unavailable as a legal treatment in the United States, and patients should not seek it outside regulated research settings.

Frequently Asked Questions

What is ibogaine?

Ibogaine is a psychedelic compound derived from the iboga plant, native to Central Africa. It has been used in traditional ceremonies and, more recently, in unregulated clinics abroad, mostly for addiction treatment. In the United States it is a Schedule I controlled substance.

Will veterans be able to get ibogaine treatment now?

No. The new funding only prepares for future clinical trials. It does not pay for patient treatment or authorize human studies. Veterans interested in psychedelic research should look for registered clinical trials rather than unregulated providers.

Is ibogaine safe?

Ibogaine carries a serious risk of dangerous heart rhythm problems, which have caused deaths outside medical settings. Any future clinical use would require careful cardiac screening and medical supervision. Researchers say the drug should never be taken without medical oversight.

What else is the government funding?

Alongside the $4.9 million ibogaine program, the National Institute of Mental Health has opened a $20 million funding opportunity for a research network on rapid-acting psychotropic drugs, including ketamine, esketamine and psilocybin. Award recipients will be announced in summer 2027.

The federal government’s bet on psychedelic medicine is now backed by real money and a public timeline. Whether ibogaine can clear the safety and efficacy hurdles of American clinical trials will decide if Thursday’s announcement becomes a turning point for veterans’ mental health care — or another promising idea that stalls on the way to the clinic.

Sources: